Bristol-Myers Squibb Company (BRM.DE)
XETRA - XETRA Delayed Price. Currency in EUR
Add to watchlist
As of 10:14AM CEST. Market open.
| Previous Close | 39.29 |
| Open | 39.62 |
| Bid | 38.90 x 37000 |
| Ask | 39.12 x 43000 |
| Day's Range | 39.00 - 39.62 |
| 52 Week Range | 36.90 - 59.70 |
| Volume | |
| Avg. Volume | 5,003 |
| Market Cap | 79.057B |
| Beta (5Y Monthly) | 0.43 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.23 (5.69%) |
| Ex-Dividend Date | Jul 05, 2024 |
| 1y Target Est | N/A |
- Zacks
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
- Zacks
Bristol Myers Squibb (BMY) Stock Declines While Market Improves: Some Information for Investors
In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $42.19, denoting a -0.09% change from the preceding trading day.
- Zacks
Bristol Myers' (BMY) Krazati Gets FDA Nod for Colorectal Cancer
Bristol Myers (BMY) wins FDA approval for Krazati, in combination with Erbitux, as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer.
© 2024 Yahoo. All rights reserved.